Mass. Movers

Disappointing drug results sink ArQule

Woburn-based ArQule Inc. develops cancer therapies.

Joanne Rathe/Globe Staff/File

Woburn-based ArQule Inc. develops cancer therapies.

An experimental colorectal cancer drug being developed by Woburn’s ArQule Inc. and Japan’s Daiichi Sankyo Co. Ltd. failed to improve patient survival without the cancer worsening. The midstage trial, which enrolled 122 patients, also failed to meet the secondary goal of showing improved response to the drug tivantinib. Friday’s failure is the latest in a series of bad drug-related news. It ended a lung cancer trial in October and an Asian partner halted another trial in August.

Loading comments...
Real journalists. Real journalism. Subscribe to The Boston Globe today.